Age-related macular degeneration (AMD) remains a leading cause of vision loss, but new therapies are reshaping its treatment.

In early research, OCU410ST, a gene therapy for Stargardt disease, demonstrated slowed lesion growth by 48% at the 12-month follow-up in evaluable treated eyes.

Age-related macular degeneration (AMD) remains a leading cause of vision loss globally, with significant advancements in treatment options for both ...

Harrow has entered into an agreement with Samsung Bioepis for the U.S. commercial rights to two ophthalmology biosimilars, ...

How you prepare your morning cup of joe could be linked to an eye disease that affects nearly 20 million Americans.

Canadian study reveals diabetic patients taking GLP-1 medications face twice the risk of eye problems, with longer exposure increasing danger of macular degeneration.

Whether you’re a latte lover, a mocha monster or an espresso elitist — people have strong preferences when it comes to coffee ...

To mark Ophthalmology Times' 50th anniversary, we invited top experts to reflect on the most significant innovations in ophthalmology over the past five decades.

Age-related macular degeneration is a leading cause of blindness and affects over 196 million people worldwide. Despite its prevalence, very little is known about the causes or mechanisms of this ...

Sanofi said SAR446597, its treatment for geographic atrophy due to age-related macular degeneration, was granted fast-track designation by the Food and Drug Administration. The French drugmaker said ...

A Gomersal man living with the biggest cause of sight loss is calling on more people with a diagnosis of macular disease to seek vital support as early as possible.